Philip J. Mease, MD, on Ixekizumab as a New Therapy for Psoriatic Arthritis
Philip J. Mease, MD, from Swedish Medical Center, discusses results from the phase 4 SPIRIT-H2H clinical trial that compared the safety and efficacy of ixekizumab—an interleukin-17a monoclonal antibody—with adalimumab—a tumor necrosis factor inhibitor—for psoriatic arthritis. For more content, visit consultant360.com/rheumatology.